DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Amyris Highlights Presentation Of Clinical Data Showcasing Its Sugarcane Squalane

Amyris, Inc. (NASDAQ:AMRS), a global science and technology leader of pure, sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today presented clinical data

Benzinga · 03/06/2020 13:31

Amyris, Inc. (NASDAQ:AMRS), a global science and technology leader of pure, sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today presented clinical data showcasing the superiority of its natural sugarcane squalane (marketed and sold as Neossance Squalane) as a carrier of CBD versus other oils. In order for CBD to be effective in topical applications, skin penetration is a key factor. Amyris sugarcane squalane improves the efficacy of CBD by 10-40X as the carrier oil chassis for the skin care market based on new data.

The Cosmos Technical Center* recently conducted a study to explore the skin penetration rate of CBD in Neossance Squalane versus jojoba oil, sunflower oil, MCT (medium-chain triglycerides), and hemp seed oil into human skin. The study measured the amount of CBD penetrated in a human epidermal skin model and found that Neossance Squalane delivered between 10-40 times more CBD to the epidermis than other carrier oils. The results also illustrated that CBD when used with Neossance Squalane penetrated skin faster, an important aspect for quicker and impactful skin relief.